Doron Therapeutics Secures $11M to Advance MOTYS for Knee Osteoarthritis into Phase 3 Trial
Key Insights
Doron Therapeutics (search) has raised $11 million in Series A funding to support a Phase 3 clinical trial of MOTYS (search), a novel intra-articular biologic drug for symptomatic knee osteoarthritis (search).
MOTYS (search), derived from placental tissue, aims to provide anti-inflammatory, anti-catabolic, and pro-anabolic effects through growth factors, offering a potential alternative to corticosteroids and hyaluronic acid.
Phase 2 trial data demonstrated that MOTYS (search) improved knee pain and function in participants with symptomatic knee osteoarthritis (search) over a 26-week period.
Doron Therapeutics (search) has successfully closed an $11 million Series A funding round, paving the way for a Phase 3 clinical trial of its lead drug candidate, MOTYS (search), designed for the treatment of symptomatic knee osteoarthritis (search) (OA). The funding, led by SPRIM Global Investments (SGI), will accelerate the development of this novel intra-articular biologic.
MOTYS: A Regenerative Approach to Osteoarthritis
MOTYS (search) originated from Bioventus (search) and is derived from placental tissue. Its unique mechanism of action involves delivering a combination of anti-inflammatory, anti-catabolic, and pro-anabolic effects. The drug contains growth factors that have demonstrated potential in reducing inflammation, protecting tissues, and stimulating regeneration within the affected knee joint.
Preclinical studies have indicated that MOTYS (search) is effective in in vitro and in vivo models, positioning it as a potential alternative to current standard-of-care treatments such as corticosteroids and hyaluronic acid injections. Doron Therapeutics (search) reports that a single injection of MOTYS can provide long-lasting relief, with effects lasting between 9 to 12 months.
Promising Phase 2 Results
Data from a Phase 2 clinical trial, involving 200 participants with symptomatic knee OA, were presented at the Osteoarthritis (search) Research Society International (OARSI) World Congress. The results showed significant improvements in knee pain and function over a 26-week treatment period, suggesting the therapeutic potential of MOTYS (search).
Addressing Unmet Needs in Osteoarthritis Treatment
Osteoarthritis (search) is a prevalent and debilitating condition affecting millions worldwide. Current non-surgical interventions often provide limited or temporary relief. Alessandra Pavesio, CEO of Doron, stated, "The unmet need for non-surgical interventions in osteoarthritis is immense and growing. We believe MOTYS (search) will allow patients to have reduced pain and regain function, allowing them the opportunity to get back to healthy and active lives."
The advancement of MOTYS (search) into Phase 3 trials represents a significant step forward in the development of regenerative medicine approaches for osteoarthritis (search), potentially offering a more effective and durable solution for patients suffering from this condition.